Siemens Healthineers is teaming up with Catholic non-profit health care system SSM Health in a new 10-year strategic partnership aimed at advancing access to high-quality care and training of health care workers in the Midwest region of the US.
The organisations will focus on cultivating a new generation of radiologic technologists through local imaging apprenticeship programs and community partners. The programs expect to expand employment and training opportunities for local youth through the Urban League’s Save Our Sons & Save Our Sisters initiative which helps economically disadvantaged African American men.
Siemens Healthineers and SSM will also develop access to diagnostic and imaging services for communities across SSM Health’s four-state service area, which include Illinois, Missouri, Oklahoma, and Wisconsin. To advance health equity, the organisations said they will jointly invest in programs that expand early detection and management of chronic disease for underserved and vulnerable individuals in the same communities.
“At SSM Health, we are working to ensure all people have access to high-quality, compassionate, and affordable care, but we can’t do this alone,” said Jeremy Fotheringham, regional president, SSM Health. “Siemens Healthineers shares our deep-rooted commitment to innovation, quality, and value. We are thrilled to partner with them in our mission to transform health care delivery and address the health equity gap in our communities.”
SSM Health is also expanding its relationship with Siemens Healthineers’ radiation oncology company Varian, by implementing offerings from Varian’s Advanced Oncology Solutions (AOS) portfolio.
Shares of Siemens Healthineers dropped in early trading on Wednesday 2 August after the company posted disappointing Q3 2023 results for its Varian radiation oncology business.
The German device maker reported higher net profit in its fiscal third quarter, due to lower taxes and higher revenue. Growth in the imaging and advanced-therapies segments was broadly offset by a drop in diagnostics sales due to weaker demand for Covid-19 antigen tests, the company said.
